Adagene Inc.
We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our immunotherapy pipeline. (Note: Adagene priced its IPO on Feb. 8, 2021, at $19 – the top […]
February 4, 2021 Read More